Understand the source comparison
Adamax History: Comparison of Development Phases
Phase 1 2004–2006 Receptor binding optimization Native L-amino acid sequence with extended chain length 48-hour degradation at 4°C; 70% potency loss upon reconstitution 100% baseline affinity Unusable for commercial distribution. Degraded during transport Phas
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase 1
- 2004–2006
- Receptor binding optimization
- Native L-amino acid sequence with extended chain length
- 48-hour degradation at 4°C; 70% potency loss upon reconstitution
- 100% baseline affinity
- Unusable for commercial distribution. Degraded during transport
- Phase 2
- 2006–2008
- Enzymatic resistance
- D-amino acid substitutions at positions 2, 8, 12, 15
- 6-month refrigerated stability; 20% potency loss upon reconstitution
- 80–85% baseline affinity
- Reduced potency required higher dosing; cost and solubility concerns
- Phase 3
- 2008–2010
- Balanced potency and stability
- N-terminal acetylation + selective D-substitution (positions 2, 15) + hydrophobic residue placement
- 18-month refrigerated stability; <10% potency loss
- 95–98% baseline affinity
- Commercially viable. Current Adamax formulation
- Phase 3 represents the inflection point where Adamax transitioned from a laboratory curiosity to a research-grade peptide suitable for widespread distribution. The combination of N-terminal acetylation and minimal D-amino acid substitution preserved near-native receptor affinity while achieving stability sufficient for global shipping and long-term storage. That balance. Not receptor affinity alone, not stability alone. Is what defines the compound's current form.